MedInCell Stock Plummets 20% Over Three Months, Approaching Key Support Level
MedInCell's stock experienced a significant drop this Wednesday, falling 3.95% to 21.88 euros during the session. The Montpellier-based biotech is operating in a pressured market environment, with the CAC 40 down 0.58% and the SBF 120 dropping 0.60% at the same time. Over the past three months, the stock now shows a cumulative loss of over 20%.
Today's decline brings MedInCell to 21.88 euros, very close to its identified support threshold at 21.32 euros. This level is a critical juncture: a downward breach could lead to a more pronounced correction. The stock is now trading significantly below its 50-day moving average (24.74 euros) and below its 200-day moving average (23.06 euros), indicating a gradual deterioration in its medium-term momentum.
The RSI, an indicator measuring the speed of price movements, stands at 44, which is in a middle zone that does not yet indicate overselling but confirms the lack of significant buying pressure. The price is also flirting with the lower Bollinger band (21.61 euros), highlighting the current selling pressure. The monthly volatility, established at 15.32%, remains notable for a stock of this profile.
Three-Month Trajectory Draws Attention
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
While today's drop is nearly 4%, it is the trajectory over the last three months that is noteworthy: the stock has lost 20.44% since mid-December 2025, erasing a significant portion of the gains accumulated over the previous year. However, the performance over the past twelve months remains largely positive, at +60.18%, reminding us of the significant upward journey that had pushed the stock beyond 27 euros.
This Wednesday, the correction occurs in a context of high market tension, with the VIX — the volatility barometer in the United States — reaching 29.49 points in its latest measurement, showing a sharp increase. The DAX is down 1.58% during the session in Frankfurt, while the FTSE 100 is down 0.74% in London. The next important date for MedInCell shareholders is June 16, the scheduled date for the publication of the annual results for the fiscal year 2025-2026, an event that could provide concrete elements about the financial trajectory of the group specialized in extended-release drug technologies.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
